Short Interest in BriaCell Therapeutics Corp. (NASDAQ:BCTXW) Decreases By 58.3%

BriaCell Therapeutics Corp. (NASDAQ:BCTXWGet Free Report) was the target of a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 1,500 shares, a decline of 58.3% from the February 28th total of 3,600 shares. Based on an average daily volume of 66,600 shares, the short-interest ratio is currently 0.0 days.

BriaCell Therapeutics Stock Performance

BCTXW traded down $0.01 during midday trading on Friday, reaching $0.09. 14,109 shares of the company were exchanged, compared to its average volume of 102,936. BriaCell Therapeutics has a one year low of $0.07 and a one year high of $1.39. The company’s fifty day moving average price is $0.12 and its 200 day moving average price is $0.24.

BriaCell Therapeutics Company Profile

(Get Free Report)

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.

Read More

Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.